Solara Active Pharma Sciences Ltd's Q4FY25 Quarter Results
- 16 May 2025
Result Summary
- Solara Active Pharma Sciences Ltd reported a 0.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 21.8%.
- Its expenses for the quarter were up by 17.7% QoQ and down 9.1% YoY.
- The net profit decreased 3254.9% QoQ and decreased 6888.0% YoY.
- The earnings per share (EPS) of Solara Active Pharma Sciences Ltd declined at 70.9 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 301.13 | 301.80 | 385.30 | -0.2% | -21.8% |
Total Expenses | 345.61 | 293.71 | 380.26 | 17.7% | -9.1% |
Profit Before Tax | -166.66 | 8.09 | 5.04 | -2160.1% | -3406.7% |
Tax | 88.79 | 0.00 | 1.28 | - | 6836.7% |
Profit After Tax | -255.23 | 8.09 | 3.76 | -3254.9% | -6888.0% |
Earnings Per Share | -70.90 | 2.00 | 1.10 | -3645.0% | -6545.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Solara Active Pharma Sciences Ltd is a company engaged in the pharmaceutical industry, primarily involved in the production and marketing of active pharmaceutical ingredients (APIs). The company focuses on the development and manufacture of a wide range of APIs used in various therapeutic categories. Given the pharmaceutical sector's critical role in healthcare, companies like Solara play a significant part in the supply chain of essential drugs. While specific recent developments for Solara Active Pharma Sciences Ltd are not available in the provided data, companies in this sector often experience dynamics related to regulatory changes, market demand shifts, and innovation in drug development.
Revenue
For the fourth quarter of fiscal year 2025 (Q4FY25), Solara Active Pharma Sciences Ltd reported a total income of ₹301.13 crores. This represents a slight decrease of 0.2% from the previous quarter (Q3FY25), where the total income was ₹301.80 crores. Compared to the same quarter last year (Q4FY24), the total income saw a significant decrease of 21.8%, down from ₹385.30 crores. Such changes in revenue can be attributed to various factors such as market conditions, product demand, pricing strategies, and competitive dynamics within the pharmaceutical industry.
Profitability
In terms of profitability, Solara Active Pharma Sciences Ltd recorded a notable shift in its financial performance. The company reported a loss before tax of ₹166.66 crores in Q4FY25, a significant change from a profit of ₹8.09 crores in Q3FY25 and ₹5.04 crores in Q4FY24. This indicates a substantial deterioration in profitability over both the quarter-on-quarter (QoQ) and year-over-year (YoY) periods. The reported tax for Q4FY25 was ₹88.79 crores, compared to zero tax in the previous quarter and ₹1.28 crores in Q4FY24. The profit after tax also reflected a marked decline, with a loss of ₹255.23 crores in Q4FY25 compared to a profit of ₹8.09 crores in Q3FY25 and ₹3.76 crores in Q4FY24.
Operating Metrics
The financial data highlights key operating metrics that underscore the company's financial health and performance. Earnings per share (EPS) for Q4FY25 was reported as negative ₹70.90, a sharp decline from ₹2.00 in Q3FY25 and ₹1.10 in Q4FY24. These figures reflect the impact of the company's reported losses on shareholder value. The total expenses for Q4FY25 amounted to ₹345.61 crores, representing an increase of 17.7% from the previous quarter's ₹293.71 crores, but a decrease of 9.1% compared to ₹380.26 crores in Q4FY24. These expense trends may reflect changes in operational costs, investment in research and development, or other financial commitments.